Drug targets are proteins expressed by human genes that can be used to discover and develop small molecule drugs. In the last 100 years of pharmaceutical research, some 500 drug targets based on human genes (of which there are approximately 100,000) have been identified worldwide for use in the development of medical therapies, leaving a considerable number of potential targets still to be discovered.
Bayer is an international, research-based group with major businesses in health care, agriculture, polymers and specialty chemicals. With some 120,000 employees worldwide, the group recorded a net income of 2 billion euros on sales of 27.3 billion euros in 1999. For the current year, 2.4 billion euros are budgeted for capital expenditures and 2.2 billion euros for research and development.
Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium also strives to accelerate the process of drug discovery and development. Headquartered in Cambridge, Mass., Millennium and its affiliates currently employ more than 1,200 people.
Contact: Maureen Suda, Millennium Pharmaceuticals Inc.